Real-time insights into regulatory activities across 55 African countries
AMA harmonized products driving regional adoption and regulatory convergence
Continental listings represent products that have passed AMA's rigorous evaluation process, enabling faster national approvals through reliance pathways. With 2 countries already granting approvals, this demonstrates the tangible impact of regulatory harmonization in reducing market access barriers and accelerating availability of quality-assured medicines across Africa.
Comprehensive database of registered pharmaceutical products across Africa
The pharmaceutical products registry provides transparency into the regulatory pipeline across African countries. Status distribution reveals regulatory capacity and efficiency at national levels, helping identify where bottlenecks exist and where streamlining efforts should focus to accelerate access to essential medicines.
Comprehensive overview of regulatory activities, capacity, and engagement across all 55 African countries
Manufacturing origin analysis - domestic vs imported pharmaceutical products
The local vs foreign distribution reveals pharmaceutical manufacturing capacity and import dependency across Africa. A higher proportion of local products indicates stronger domestic pharmaceutical industry, while foreign products highlight reliance on imports. This data informs policies on local production incentives, technology transfer, and regional manufacturing hubs to enhance pharmaceutical self-sufficiency.
Top 10 countries with highest pharmaceutical product registrations
Countries with higher product registrations typically have more robust regulatory frameworks, larger pharmaceutical markets, and stronger healthcare systems. This distribution helps identify regulatory leaders in Africa and highlights opportunities for capacity building in countries with lower registration numbers. It also reveals market attractiveness for pharmaceutical companies and potential for regional regulatory cooperation.
Research activities across the continent
112 clinical trials demonstrate Africa's growing role in global pharmaceutical research, building capacity for evidence-based medicine.
Registered medical devices and equipment
Post-market surveillance and adverse event reporting across Africa
Active pharmacovigilance across 3 organizations demonstrates commitment to post-market safety surveillance. This reporting network enables rapid identification of safety signals, protecting public health while building confidence in regulatory systems across the continent.
Tracking progress on AMA Continental Core Indicators for regulatory strengthening
| Indicator Name | Outcome | Submissions | Avg Value |
|---|---|---|---|
| Proportion of countries with formal procedures or guidelines or policies for implementing reliance | Enhanced policy coherence and legal frameworks | 12 | 4.3% |
| Proportion of countries domesticating harmonised policies and guidelines for regulation of medical products | Enhanced policy coherence and legal frameworks | 11 | 4.2% |
| Proportion of continental harmonised guidance documents domesticated | Enhanced policy coherence and legal frameworks | 11 | 3.6% |
| Proportion of countries that have domesticated the AU Model Law on Medical Products Regulation and technologies | Enhanced policy coherence and legal frameworks | 11 | 4.5% |
| Proportion of countries that have ratified the AMA treaty | Enhanced policy coherence and legal frameworks | 10 | 4% |
The M&E system tracks 22 continental core indicators across 3 outcomes: enhanced policy coherence, strengthened regulatory systems, and improved regulatory capacity. With 8 countries actively reporting, this data-driven approach enables evidence-based decision-making and demonstrates measurable progress toward regulatory excellence across Africa.